In most low-and middle-resource countries (LMCs), breast cancer incidence rates are increasing more rapidly than in regions where incidence rates already are high. Despite the younger age structure of most developing countries, LMCs already account for 45% of the incident breast cancer cases and cause 54% of the annual breast cancer deaths around the globe. 1 Even assuming (conservatively) that there will be no change in underlying age-specific rates, a nearly 50% increase is anticipated in breast cancer global incidence and mortality between the years 2002 and 2020 caused simply by the aging of current global populations. These rising cancer rates will be disproportionately greater among countries in the developing world, and the rates in LMCs are projected to reach a 55% increased incidence and a 58% increased mortality in <20 years. 1 In reality, these projected statistics probably underestimate future cancer rates, because the few data available from LMCs reveal increasing age-specific breast cancer incidence and mortality rates, especially among recent birth cohorts. This is especially true for urban women in LMCs and is attributable in part to the adoption of Western lifestyles. 2,3 Improvements in breast cancer survival in the industrialized world that have been observed in recent decades can be attributed to early detection by screening combined with timely and effective treatment as guided by the results of extensive and rigorously performed clinical trials. 4 Randomized trials of screening mammography combined with clinical breast examination (CBE) initiated in the 1970s demonstrated that early cancer detection within a given population leads to down-staging of disease and improvement in breast cancer survival. At the same time, randomized trials of systemic therapies for breast cancer proved that endocrine therapy for estrogen receptor (ER)-positive cancers and cytotoxic chemotherapy for ER-negative cancers improve survival and produce durable long-term cure among patients with lymph node negative, lymph node positive, and even locally advanced breast cancers. 5 Breast cancer mortality essentially was unchanged in the United States for 6 decades between 1930 and 1990. By contrast, since 1990, age-adjusted breast cancer mortality has been dropping by nearly 2% each year in the United States, indicating that true progress is being made in the management of this disease. 6 Similar improvements also are being observed in Western European countries that have invoked population-wide early detection and adjuvant treatment programs.Notably, minority women in the United States are more likely to present with advanced stage disease and have higher mortality rates than white women, although white women and black women who present with similar stage disease and receive similar treatment have similar outcomes. These findings suggest that differences in stage at presentation should represent a primary target for research, the goal of which is to determine which interventions best reduce disparities in cancer outcom...